Boston, MANCT07159841Now EnrollingIRB Ready

Congenital Adrenal Hyperplasia Clinical Trial in Boston, MA

Access cutting-edge congenital adrenal hyperplasia treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Crinetics Pharmaceuticals Inc.

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access congenital adrenal hyperplasia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related congenital adrenal hyperplasia treatment provided free

Apply for This Boston Location

Check if you qualify for this congenital adrenal hyperplasia clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Congenital Adrenal Hyperplasia Study in Boston

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

Sponsor: Crinetics Pharmaceuticals Inc.

Who Can Participate

Inclusion Criteria

Part A and B participants are eligible to be included in the study only if all of the following criteria apply:
Male or female at birth, between 1 to \<18 years of chronological age at the time of signing the Informed Consent Form (ICF).
Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency (21-OHD) based on standard medically accepted criteria such as elevated 17-OHP level, confirmed CYP21A2 genetic testing, positive newborn screening with confirmatory second tier testing, or cosyntropin stimulation.
Participants must have an elevated morning serum A4 level \>ULN during Screening obtained prior to morning glucocorticoid (GC) administration.
Participants must be on a stable supraphysiologic GC replacement therapy for at least one month prior to Screening.
Compliance, as judged per Investigator discretion, with GC replacement and mineralocorticoid replacement (if applicable) regimen documented during the Screening Period.
Biochemical euthyroidism as determined by the Investigator. Part C inclusion criteria require participants to complete treatment in either Part A or Part B and in the Investigator's opinion it would benefit the participant to continue in Part C, regardless of age.

Exclusion Criteria

Part A and Part B: Individuals in Part A and Part B who meet any of the following criteria will be excluded from participation in this study:
Diagnosis of any form of CAH other than classic 21-OHD.
Participants treated with other GCs within 30 days of Screening.
Stress dose of GC therapy within 2 weeks of start of Screening, defined as any dose above the normal maintenance dose, including but not limited to intravenous (IV) or intramuscular (IM) hydrocortisone.
Use of growth hormones within 1 week of start of Screening for short acting, or within 6 weeks of start of Screening for long acting.
Use of a corticotropin-releasing factor receptor antagonist within 14 days of Screening.
History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ.
Abnormal sleep/wake cycles (as determined by the Investigator).
Female participants who are pregnant or lactating.
Participants who have been dosed with an investigational drug (including atumelnant) in any prior clinical study within 60 days or 5 half-lives (whichever is longer) prior to the first dose.
Individuals in Part C who do not meet the Part C Inclusion Criteria.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07159841) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Congenital Adrenal Hyperplasia Treatment Options in Boston, MA

If you're searching for congenital adrenal hyperplasia treatment options in Boston, MA, this clinical trial (NCT07159841) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced congenital adrenal hyperplasia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all congenital adrenal hyperplasia clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Boston, MA

See all pulmonary embolism clinical trials recruiting in Boston — not just this study.

Browse Pulmonary Embolism Trials in Boston →

Browse More Trials by Condition

Pulmonary Embolism TrialsAlzheimers Disease TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsRetinitis Pigmentosa TrialsRecurrent Pregnancy Loss TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA